BeiGene, Ltd. (ONC) is a Healthcare · Biotechnology company listed on NASDAQ. Price $350.84 (-0.74%), Market cap $30.43B, P/E ratio 66.20, 52-week low–high $233.37 ~ $377.47.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products com
Financial statements, price targets, institutional (13F) holdings and related news for BeiGene, Ltd. are updated in real time on BlackAll Trade.
BeiGene, Ltd. trades at $350.84 (-0.74%). Real-time quotes and charts are available on BlackAll Trade.
BeiGene, Ltd. has a market cap of about $30.43B. Its P/E ratio is 66.20.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial